Reperfusion injury is the damage to tissues
caused when blood supply returns to the tissue after a period of ischemia or
lack of oxygen (anoxia, hypoxia). It influences the patient’s outcome after
myocardial infarction, stroke, cardiovascular surgery, and organ
transplantation.
Access
Detailed Report Summary:
The
treatments available for reperfusion injury are therapeutic hypothermia,
hydrogen sulfide treatment, cyclosporin, stem cell therapy and metformin.
Radikal Therapeutics Inc. is in the process of developing R-190 as an
intravenous formulation for the treatment of limb ischemia reperfusion injury.
The drug candidate is being developed as a small molecule which acts as a
nitric oxide donors and reactive oxygen species inhibitor. Some of the
companies having a pipeline of reperfusion injury include Catalyst Biosciences
Inc., MIFCOR Inc. and others.
Request
to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1148
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment